

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
(19) World Intellectual Property

Organization
International Bureau

(43) International Publication Date
17 December 2015 (17.12.2015)



(10) International Publication Number
WO 2015/191312 A1

- (51) International Patent Classification:
A61K 39/395 (2006.01) C07K 14/50 (2006.01)
- (21) International Application Number:
PCT/US2015/033226
- (22) International Filing Date:
29 May 2015 (29.05.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/009,474 9 June 2014 (09.06.2014) US
- (71) Applicants: **ULTRAGENYX PHARMACEUTICAL INC.** [US/US]; 60 Leveroni Court, Novato, California 94949 (US). **KYOWA HAKKO KIRIN CO., LTD.** [JP/JP]; 1-6-1, Ohtemachi, Chiyoda-ku, Tokyo 100-8185 (JP).
- (72) Inventors: **KAKKIS, Emil**; 546 Biscayne Drive, San Rafael, California 94901 (US). **SAN MARTIN, Javier**; c/o Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, California 94949 (US). **SUDO, Tomohiro**; 1-6-1, Ohtemachi, Chiyoda-ku, Tokyo 100-8185 (JP).
- (74) Agents: **WU, Nan** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004-2400 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: THE EFFECTIVE AND EFFICIENT CONTROL OF SERUM PHOSPHATE FOR OPTIMAL BONE FORMATION

FIG. 1 Mean ($\pm$ SD) Serum Phosphorus Values by Study Day – All Subjects Treated with KRN23 (Efficacy Analysis Set)



(57) Abstract: The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.